Full Press Release Details
LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia , M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston .
Details of the presentation are as follows:
Title: Armata Clinical Trials Overview of Bacteriophage Administration for Difficult-To-Treat Infections
Day: Wednesday, February 28
Time: 12:00 p.m. ET
Location: Wyndham Boston Beacon Hill
Dr. Pastagia's presentation will cover a range of topics related to Armata's ongoing development programs, including:
The Summit's 2024 program is centered around optimizing safety, efficacy and manufacturing of next generation bacteriophage therapy to demonstrate positive clinical data and patient outcomes. With the promising possibility of bacteriophage therapy entering the market, the industry is on a run to advance clinical and regulatory development, improve manufacturability, enhance delivery strategies, explore phage-antibiotic synergies, and foster innovation with phage engineering and AI applications. The Summit is the only global platform for industry-dominated phage drug developers and will integrate 90+ phage experts. For more information, or to register for the Summit, use this link .
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Media Contacts:
At Armata: Pierre Kyme Armata Pharmaceuticals, Inc. [email protected] 310-665-2928 x234
Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.